1
|
Oprea-Lager DE, Gontier E, García-Cañamaque L, Gauthé M, Olivier P, Mitjavila M, Tamayo P, Robin P, García Vicente AM, Bouyeure AC, Bailliez A, Rodríguez-Fernández A, Mahmoud SB, Vallejo-Casas JA, Maksud P, Merlin C, Blanc-Durand P, Drouet C, Tissot H, Vierasu I, Vander Borght T, Boos E, Chossat F, Hodolic M, Rousseau C. [ 18F]DCFPyL PET/CT versus [ 18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study. Eur J Nucl Med Mol Imaging 2023; 50:3439-3451. [PMID: 37341747 PMCID: PMC10542307 DOI: 10.1007/s00259-023-06301-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Accepted: 06/05/2023] [Indexed: 06/22/2023]
Abstract
PURPOSE Primary objective was to compare the per-patient detection rates (DR) of [18F]DCFPyL versus [18F]fluoromethylcholine positron emission tomography/computed tomography (PET/CT), in patients with first prostate cancer (PCa) biochemical recurrence (BCR). Secondary endpoints included safety and impact on patient management (PM). METHODS This was a prospective, open label, cross-over, comparative study with randomized treatment administration of [18F]DCFPyL (investigational medicinal product) or [18F]fluoromethylcholine (comparator). Men with rising prostate-specific antigen (PSA) after initial curative therapy were enrolled. [18F]DCFPyL and [18F]fluoromethylcholine PET/CTs were performed within a maximum time interval of 12 days. DR was defined as the percentage of positive PET/CT scans identified by 3 central imaging readers. PM was assessed by comparing the proposed pre-PET/CT treatment with the local treatment", defined after considering both PET/CTs. RESULTS A total of 205 patients with first BCR after radical prostatectomy (73%; median PSA = 0.46 ng/ml [CI 0.16;27.0]) or radiation therapy (27%; median PSA = 4.23 ng/ml [CI 1.4;98.6]) underwent [18F]DCFPyL- and/or [18F]fluoromethylcholine -PET/CTs, between July and December 2020, at 22 European sites. 201 patients completed the study. The per-patient DR was significantly higher for [18F]DCFPyL- compared to [18F]fluoromethylcholine -PET/CTs (58% (117/201 patients) vs. 40% (81/201 patients), p < 0.0001). DR increased with higher PSA values for both tracers (PSA ≤ 0.5 ng/ml: 26/74 (35%) vs. 22/74 (30%); PSA 0.5 to ≤ 1.0 ng/ml: 17/31 (55%) vs. 10/31 (32%); PSA 1.01 to < 2.0 ng/ml: 13/19 (68%) vs. 6/19 (32%);PSA > 2.0: 50/57 (88%) vs. 39/57 (68%) for [18F]DCFPyL- and [18F]fluoromethylcholine -PET/CT, respectively). [18F]DCFPyL PET/CT had an impact on PM in 44% (90/204) of patients versus 29% (58/202) for [18F]fluoromethylcholine. Overall, no drug-related nor serious adverse events were observed. CONCLUSIONS The primary endpoint of this study was achieved, confirming a significantly higher detection rate for [18F]DCFPyL compared to [18F]fluoromethylcholine, in men with first BCR of PCa, across a wide PSA range. [18F]DCFPyL was safe and well tolerated.
Collapse
Affiliation(s)
- Daniela-Elena Oprea-Lager
- Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
| | - Eric Gontier
- Service de Médecine Nucléaire, Centre de Cancérologie de La Sarthe, Le Mans, France
| | - Lina García-Cañamaque
- Servicio de Medicina Nuclear, Grupo HM Hospitales, Universidad CEU San Pablo, Madrid, Spain
| | - Mathieu Gauthé
- Service de Médecine Nucléaire, Hôpital Tenon, Paris, France
| | | | - Mercedes Mitjavila
- Servicio de Medicina Nuclear, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | - Pilar Tamayo
- Servicio de Medicina Nuclear, IBSAL, Hospital Universitario de Salamanca, Salamanca, Spain
| | - Philippe Robin
- Service de Médecine Nucléaire, Centre Hospitalier Universitaire de Brest, Brest, France
- UMR 1304, Inserm, Univ Brest, CHRU Brest, GETBO, Brest, France
| | | | | | - Alban Bailliez
- Service de Médecine Nucléaire Humanitep, Groupement Des Hôpitaux de L'Institut Catholique de Lille, Hôpital Saint-Philibert, Lomme, France
- Service de Médecine Nucléaire, Hôpital Privé Le Bois, Iris Imagerie, Lille, France
| | - Antonio Rodríguez-Fernández
- Servicio de Medicina Nuclear, Hospital Universitario Virgen de Las Nieves, Granada, Spain
- Instituto de Investigación Biosanitaria IBS, Granada, Spain
| | - Sinan Ben Mahmoud
- Service de médecine nucléaire, Hôpital de Mercy, CHR Metz-Thionville, Thionville, France
| | - Juan Antonio Vallejo-Casas
- UGC Medicina Nuclear, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Córdoba, Spain
| | - Philippe Maksud
- Service de médecine nucléaire Hôpital de la Pitié-Salpétriére, Sorbonne-Université, Paris, France
| | - Charles Merlin
- Service de médecine nucléaire, Centre Jean Perrin, Clermont-Ferrand, France
- Imagerie moléculaire et stratégies théranostiques, UMR1240, Université Clermont Auvergne, Inserm, Clermont-Ferrand, France
| | - Paul Blanc-Durand
- Service de médecine nucléaire, CHU H. Mondor, Créteil, France; Université Paris Est Créteil (U-PEC), Créteil, France
| | - Clément Drouet
- Service de médecine nucléaire, Centre Georges-François-Leclerc, Dijon, France
| | - Hubert Tissot
- Service de médecine nucléaire, Institut Curie, Paris, France
| | - Irina Vierasu
- Department of Nuclear Medicine, HUB, Hôpital Erasme Université libre de Bruxelles (ULB), Brussels, Belgium
| | | | | | | | | | - Caroline Rousseau
- Univ Nantes, Univ Angers, INSERM, CNRS, CRCI2NA, Nantes, France
- Service de médecine nucléaire, Institut de cancérologie de l'Ouest, Saint-Herblain, France
| |
Collapse
|
2
|
Bonnin D, Ladoire S, Briot N, Bertaut A, Drouet C, Cochet A, Alberini JL. Performance of [18F]FDG-PET/CT Imaging in First Recurrence of Invasive Lobular Carcinoma. J Clin Med 2023; 12:jcm12082916. [PMID: 37109252 PMCID: PMC10144846 DOI: 10.3390/jcm12082916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 04/04/2023] [Accepted: 04/13/2023] [Indexed: 04/29/2023] Open
Abstract
BACKGROUND Invasive lobular carcinoma accounts for 10 to 15% of all breast cancers. The first objective of this retrospective study was to assess the diagnostic performance of FDG-PET/CT scanning in women previously treated for invasive lobular carcinoma with suspected first recurrence. The secondary objectives were to evaluate the impact of PET/CT in a change in treatment and its prognostic value on specific survival. METHODS Patients in whom a PET/CT scan was performed from January 2011 to July 2019 in our Cancer Research Center were enrolled. Recurrence was suspected based on clinical symptoms, abnormal findings on conventional imaging, and/or elevated tumor markers. The diagnosis of recurrence was established by the oncologist after integration of all clinical, biological, histological, imaging, and follow-up data. Prognostic factors of recurrence as predicted by PET were determined using univariate logistic regression. KI67, mitotic index, or grade of mitosis were tested. Survival curves were compared using the log-rank test. Sixty-four patients (mean age: 60.3; SD = 12.4 years) were enrolled. The average time from initial diagnosis of the primary tumor to suspicion of recurrence was 5.2 ± 4.1 years. Forty-eight patients (75%) were judged to have recurrence by the oncologist: 7 local and 41 metastatic, with mainly bone (n = 24), lymph node (n = 14) and liver (n = 10) metastases. RESULTS Sensitivity, specificity, and positive and negative predictive values of PET/CT to predict recurrence were, respectively: 87%, 87%, 95%, and 70%. SUVmax at recurrence sites was generally high (mean: 6.4; SD = 2.9). False negative PET/CT results occurred with local (n = 2), peritoneal (n = 2), meningeal (n = 1), or bladder (n = 1) recurrences. In 40 patients with available histopathological data from suspected sites of recurrence, 30 PET/CT were true positive. In four patients, primary lung (n = 1) or gastric (n = 1) tumors or lymphomas (n = 2) were found. The detection of a recurrence resulted in a change in treatment in 44/48 patients (92%). No association between recurrence predicted by PET and biological biomarkers was found. Median specific survival appears shorter in patients with metastatic recurrence versus patients with local or no recurrence on PET/CT (p = 0.067). CONCLUSIONS FDG-PET/CT is an effective and reliable tool for the detection of invasive lobular carcinoma recurrence, although certain recurrence sites specific to this histological type can impair its diagnostic performance.
Collapse
Affiliation(s)
- David Bonnin
- Department of Nuclear Medicine, Georges Francois Leclerc Research Cancer Center, 21079 Dijon, France
| | - Sylvain Ladoire
- Department of Medical Oncology, Georges Francois Leclerc Research Cancer Center; 21000 Dijon, France
- Research Center INSERM LNC-UMR1231, 21000 Dijon, France
| | - Nathalie Briot
- Department of Methodology and Biostatistics, Georges-Francois Leclerc Research Cancer Center, 21000 Dijon, France
| | - Aurélie Bertaut
- Department of Methodology and Biostatistics, Georges-Francois Leclerc Research Cancer Center, 21000 Dijon, France
| | - Clément Drouet
- Department of Nuclear Medicine, Georges Francois Leclerc Research Cancer Center, 21079 Dijon, France
| | - Alexandre Cochet
- Department of Nuclear Medicine, Georges Francois Leclerc Research Cancer Center, 21079 Dijon, France
- Laboratoire ICMUB, University Bourgogne, 21000 Dijon, France
| | - Jean-Louis Alberini
- Department of Nuclear Medicine, Georges Francois Leclerc Research Cancer Center, 21079 Dijon, France
- Laboratoire ICMUB, University Bourgogne, 21000 Dijon, France
- Centre Georges-Francois Leclerc, 1 rue du Pr Marion, 21079 Dijon CEDEX, France
| |
Collapse
|
3
|
Bonnefoy PB, Janvier L, Arede C, Drouet C, Harami D, Marque S, Ahond-Vionnet R. Reduced acquisition time for thallium myocardial perfusion imaging with large field cadmium-zinc-telluride SPECT/CT cameras: An equivalence study. J Nucl Cardiol 2022; 29:1933-1941. [PMID: 33890184 DOI: 10.1007/s12350-021-02611-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2020] [Accepted: 03/03/2021] [Indexed: 11/27/2022]
Abstract
BACKGROUND Cadmium-zinc-telluride (CZT) SPECT/CT cameras with large field of view offer a higher sensitivity than conventional Anger cameras. This prospective study aimed to determine the equivalence between a conventional protocol and a reduced acquisition time protocol for 201-Thallium myocardial perfusion imaging (MPI) using a whole-body CZT SPECT camera. METHODS AND RESULTS Stress MPI was obtained for 103 consecutive patients on a DISCOVERY-CZT camera. Images were anonymized and post-processed to simulate a 25% (D75 dataset) and 50% (D50 dataset) decrease in total recorded counts. Concerning the number of segments displaying a tracer uptake < 70% of maximum intensity per patient, equivalence was demonstrated for both count-reduced datasets with a good inter-observer agreement (between 0.90 and 0.88). When comparing the full-vs-D75 datasets and full-vs-D50 datasets, mean difference was 0.06 segment (CI95: [- 0.15;0.27], P < 0.001) and 0.518 segment (CI95: [0.28;0.76], P < 0.001) respectively. Inter-observer agreement was also moderate to good concerning the number of pathological segments (between 0.6 and 0.7) and excellent for functional parameters. CONCLUSION Whole-body CZT SPECT/CT cameras allow to reduce 201-Thallium MPI injected activity or acquisition time by 50% with an equivalence in the number of segments displaying a tracer uptake < 70% of maximum intensity and with a good inter-observer agreement.
Collapse
Affiliation(s)
- P B Bonnefoy
- Service de Médecine Nucléaire, Hôpital Pierre Bérégovoy, Nevers, France.
- Service de Médecine Nucléaire, CHU Saint-Etienne - Hôpital Nord, Saint Etienne, France.
- Service de Médecine Nucléaire, CHU de Saint-Etienne, 42055, Saint-Étienne, France.
| | - L Janvier
- Service de Médecine Nucléaire, Hôpital Pierre Bérégovoy, Nevers, France
| | - C Arede
- Service de Médecine Nucléaire, Hôpital Pierre Bérégovoy, Nevers, France
| | - C Drouet
- Service de Médecine Nucléaire, Hôpital Pierre Bérégovoy, Nevers, France
- Service de Médecine Nucléaire, Centre Georges-François Leclerc, Dijon, France
| | - D Harami
- Service de Médecine Nucléaire, Hôpital Pierre Bérégovoy, Nevers, France
| | - S Marque
- Société CAPIONIS, Bordeaux, France
| | - R Ahond-Vionnet
- Service de Médecine Nucléaire, Hôpital Pierre Bérégovoy, Nevers, France
| |
Collapse
|
4
|
Thibault T, Durand-Bailloud B, Soudry-Faure A, Greigert H, Drouet C, Devilliers H, Ramon A, Bejot Y, Martin L, Creuzot-Garcher C, Falvo N, Audia S, Cochet A, Bonnotte B, Alberini JL, Samson M. PET/CT of cranial arteries for a sensitive diagnosis of giant cell arteritis. Rheumatology (Oxford) 2022; 62:1568-1575. [PMID: 35866984 DOI: 10.1093/rheumatology/keac430] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Revised: 06/16/2022] [Accepted: 07/17/2022] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES To investigate the performance of cranial PET/CT for the diagnosis of giant cell arteritis (GCA). METHODS All patients with a suspected diagnosis of GCA were prospectively enrolled in this study and had a digital PET/CT with evaluation of cranial arteries if they had not started glucocorticoids more than 72 hours previously. The diagnosis of GCA was retained after at least 6 months of follow-up if no other diagnosis was considered by the clinician and the patient went into remission after at least 6 consecutive months of treatment. Cranial PET/CT was considered positive if at least one arterial segment showed hypermetabolism similar to or greater than liver uptake. RESULTS For cranial PET/CT, sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) were 73.3%, 97.2%, 91.7% and 89.7%, respectively. For extracranial PET/CT, diagnostic performance was lower (Se = 66.7%, Sp = 80.6%, PPV = 58.8%, NPV = 85.3%). The combination of cranial and extracranial PET/CT improved overall sensitivity (Se = 80%) and NPV (NPV = 90.3%) while decreasing overall specificity (Sp = 77.8%) and PPV (PPV = 60%). CONCLUSION Cranial PET/CT can be easily combined with extracranial PET/CT with a limited increase in examination time. Combined cranial and extracranial PET/CT showed very high diagnostic accuracy for the diagnosis of GCA. TRIAL REGISTRATION ClinicalTrials.gov, https://clinicaltrials.gov, NCT05246540.
Collapse
Affiliation(s)
- Thomas Thibault
- Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France
| | | | - Agnès Soudry-Faure
- Direction of Clinical Research and Innovation (DRCI), Clinical Research Unit-Methodological Support Network (USMR), Dijon University Hospital, 21000 Dijon, France
| | - Hélène Greigert
- Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France.,Department of Vascular Medicine, Dijon University Hospital, Dijon, France.,Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-21000 Dijon, France
| | - Clément Drouet
- Department of Nuclear Medicine, Centre Georges François Leclerc, 21000 Dijon, France
| | - Hervé Devilliers
- Department of Internal Medicine and Systemic Diseases, Dijon University Hospital, Dijon, France 7 - Department of Rheumatology, Dijon University Hospital, Dijon, France
| | - André Ramon
- Department of Neurology, Dijon University Hospital, Dijon, France
| | - Yannick Bejot
- Department of Neurology, Dijon University Hospital, Dijon, France
| | - Laurent Martin
- Department of Pathology, Dijon University Hospital, Dijon, France
| | | | - Nicolas Falvo
- Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France
| | - Sylvain Audia
- Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France.,Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-21000 Dijon, France
| | - Alexandre Cochet
- Department of Nuclear Medicine, Centre Georges François Leclerc, 21000 Dijon, France.,Department of Nuclear Medicine, Dijon University Hospital, Dijon, France.,ImViA EA 7535, Université Bourgogne Franche-Comté, F-21000 Dijon, France
| | - Bernard Bonnotte
- Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France.,Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-21000 Dijon, France
| | - Jean-Louis Alberini
- Department of Nuclear Medicine, Centre Georges François Leclerc, 21000 Dijon, France.,Department of Nuclear Medicine, Dijon University Hospital, Dijon, France.,ImViA EA 7535, Université Bourgogne Franche-Comté, F-21000 Dijon, France
| | - Maxime Samson
- Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France.,Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-21000 Dijon, France
| |
Collapse
|
5
|
Darley L, Drouet C, Cochet A. [Internal jugular venous thrombosis and esophageal adenocarcinoma]. Rev Prat 2022; 72:419. [PMID: 35638988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Subscribe] [Scholar Register] [Indexed: 12/20/2023]
Affiliation(s)
| | | | - Alexandre Cochet
- "Service de médecine nucléaire, CGFL, Dijon, France Université de Bourgogne Franche-Comté, UFR sciences médicales et pharmaceutiques, Dijon, France"
| |
Collapse
|
6
|
Roland A, Drouet C, Boulahdour H, Cochet A, De Bari B. Unusual uptakes on 18F-fluorocholine positron emission tomography/computed tomography (PET/CT): a retrospective study of 368 prostate cancer patients referred for a biochemical recurrence or an initial staging. Quant Imaging Med Surg 2021; 11:172-182. [PMID: 33392020 DOI: 10.21037/qims-19-981] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Background 18F-fluorocholine positron emission tomography/computed tomography (F-choline PET/CT) is considered a cornerstone in the staging and restaging of patients with prostate cancer (PCa). The aim of this study was to retrospectively assess unusual uptakes in patients who underwent a F-choline PET/CT for the initial staging or for the restaging of a relapsing PCa. Methods Three hundred and sixty-eight PCa patients were staged or restaged using F-choline PET/CT. Unusual uptakes were defined as uptakes occurring outside the usual paths of diffusion of PCa or as uptake in bone with a clear morphological evidence of nonmetastatic lesion. Results We found unusual uptakes in 47/368 patients (12.8%). Among them, 41/47 presented with benign F-choline uptake, usually within lymph nodes, due to inflammatory processes (22/47). Other benign processes were found in: thyroid (3/47), adrenal gland (3/47), brain (2/47), liver (1/47), bowel (3/47), frontal sinus (1/47), lungs (4/47), parotid gland (1/47) and bone (1/47). The six remaining patients presented with a second cancer, including lymphoma (1/47), non-small cell lung cancer (4/47) and neuroendocrine tumor (1/47). Conclusions unusual uptakes on F-choline PET/CT are quite frequent and should be explored since they may correspond to non-PCa.
Collapse
Affiliation(s)
- Antoine Roland
- Nuclear Medicine Department, University Hospital of Besançon, Besançon, France
| | - Clément Drouet
- Department of Nuclear Medicine, Georges-François Leclerc Cancer Center, Dijon, France
| | - Hatem Boulahdour
- Nuclear Medicine Department, University Hospital of Besançon, Besançon, France
| | - Alexandre Cochet
- Department of Nuclear Medicine, Georges-François Leclerc Cancer Center, Dijon, France.,ImViA EA 7535, University of Burgundy, Dijon, France
| | - Berardino De Bari
- Radiation Oncology Department, University Hospital of Besançon, Besançon, France
| |
Collapse
|
7
|
Manrique JA, Lopez-Reyes G, Cousin A, Rull F, Maurice S, Wiens RC, Madsen MB, Madariaga JM, Gasnault O, Aramendia J, Arana G, Beck P, Bernard S, Bernardi P, Bernt MH, Berrocal A, Beyssac O, Caïs P, Castro C, Castro K, Clegg SM, Cloutis E, Dromart G, Drouet C, Dubois B, Escribano D, Fabre C, Fernandez A, Forni O, Garcia-Baonza V, Gontijo I, Johnson J, Laserna J, Lasue J, Madsen S, Mateo-Marti E, Medina J, Meslin PY, Montagnac G, Moral A, Moros J, Ollila AM, Ortega C, Prieto-Ballesteros O, Reess JM, Robinson S, Rodriguez J, Saiz J, Sanz-Arranz JA, Sard I, Sautter V, Sobron P, Toplis M, Veneranda M. SuperCam Calibration Targets: Design and Development. Space Sci Rev 2020; 216:138. [PMID: 33281235 PMCID: PMC7691312 DOI: 10.1007/s11214-020-00764-w] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Accepted: 11/09/2020] [Indexed: 05/09/2023]
Abstract
SuperCam is a highly integrated remote-sensing instrumental suite for NASA's Mars 2020 mission. It consists of a co-aligned combination of Laser-Induced Breakdown Spectroscopy (LIBS), Time-Resolved Raman and Luminescence (TRR/L), Visible and Infrared Spectroscopy (VISIR), together with sound recording (MIC) and high-magnification imaging techniques (RMI). They provide information on the mineralogy, geochemistry and mineral context around the Perseverance Rover. The calibration of this complex suite is a major challenge. Not only does each technique require its own standards or references, their combination also introduces new requirements to obtain optimal scientific output. Elemental composition, molecular vibrational features, fluorescence, morphology and texture provide a full picture of the sample with spectral information that needs to be co-aligned, correlated, and individually calibrated. The resulting hardware includes different kinds of targets, each one covering different needs of the instrument. Standards for imaging calibration, geological samples for mineral identification and chemometric calculations or spectral references to calibrate and evaluate the health of the instrument, are all included in the SuperCam Calibration Target (SCCT). The system also includes a specifically designed assembly in which the samples are mounted. This hardware allows the targets to survive the harsh environmental conditions of the launch, cruise, landing and operation on Mars during the whole mission. Here we summarize the design, development, integration, verification and functional testing of the SCCT. This work includes some key results obtained to verify the scientific outcome of the SuperCam system.
Collapse
Affiliation(s)
- J. A. Manrique
- Unidad Asocida UVA-CSIC-CAB, University of Valladolid (UVA), Valladolid, Spain
| | - G. Lopez-Reyes
- Unidad Asocida UVA-CSIC-CAB, University of Valladolid (UVA), Valladolid, Spain
| | - A. Cousin
- Institut de Recherche en Astrophysique et Planétologie (IRAP), CNRS, CNES, Université de Toulouse, Toulouse, France
| | - F. Rull
- Unidad Asocida UVA-CSIC-CAB, University of Valladolid (UVA), Valladolid, Spain
| | - S. Maurice
- Institut de Recherche en Astrophysique et Planétologie (IRAP), CNRS, CNES, Université de Toulouse, Toulouse, France
| | - R. C. Wiens
- Los Alamos National Laboratory, Los Alamos, NM USA
| | - M. B. Madsen
- Niels Bohr Institute (NBI), University of Copenhagen, Copenhagen, Denmark
| | | | - O. Gasnault
- Institut de Recherche en Astrophysique et Planétologie (IRAP), CNRS, CNES, Université de Toulouse, Toulouse, France
| | - J. Aramendia
- University of the Basque Country (UPV/EHU), Leioa, Spain
| | - G. Arana
- University of the Basque Country (UPV/EHU), Leioa, Spain
| | - P. Beck
- CNRS, Institut de Planetologie et d’Astrophysique de Grenoble (IPAG), Universite Grenoble Alpes, Saint-Martin d’Heres, France
| | - S. Bernard
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie (IMPMC), CNRS, MNHN, Sorbonne Université, Paris, France
| | - P. Bernardi
- Laboratoire d’Etudes Spatiales et d’Instrumentation en Astrophysique, Observatoire de Paris-PSL, CNRS, Sorbonne Université, Université de Paris, Meudon, France
| | - M. H. Bernt
- Niels Bohr Institute (NBI), University of Copenhagen, Copenhagen, Denmark
| | - A. Berrocal
- Ingeniería de Sistemas para la Defensa de España S.A. (ISDEFE), Madrid, Spain
| | - O. Beyssac
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie (IMPMC), CNRS, MNHN, Sorbonne Université, Paris, France
| | - P. Caïs
- Laboratoire d’astrophysique de Bordeaux, CNRS, Univ. Bordeaux, Bordeaux, France
| | - C. Castro
- Added Value Solutions (AVS), Elgóibar, Spain
| | - K. Castro
- University of the Basque Country (UPV/EHU), Leioa, Spain
| | - S. M. Clegg
- Los Alamos National Laboratory, Los Alamos, NM USA
| | | | - G. Dromart
- Univ Lyon, ENSL, CNRS, LGL-TPE, Univ Lyon 1, 69007 Lyon, France
| | - C. Drouet
- CIRIMAT, Université de Toulouse, CNRS/UT3/INP, Ensiacet, Toulouse, France
| | - B. Dubois
- Observatoire Midi-Pyrénées, Toulouse, France
| | - D. Escribano
- Instituto Nacional de Técnica Aeroespacial, Torrejón de Ardoz, Spain
| | - C. Fabre
- GeoRessources, Vandoeuvre les Nancy, France
| | | | - O. Forni
- Institut de Recherche en Astrophysique et Planétologie (IRAP), CNRS, CNES, Université de Toulouse, Toulouse, France
| | - V. Garcia-Baonza
- Instituto de Geociencias CSIC, Universidad Complutense de Madrid, Madrid, Spain
| | - I. Gontijo
- Jet Propulsion Laboratory, Pasadena, CA USA
| | - J. Johnson
- Applied Physics Laboratory, Johns Hopkins University, Laurel, MD USA
| | - J. Laserna
- University of Malaga (UMA), Málaga, Spain
| | - J. Lasue
- Institut de Recherche en Astrophysique et Planétologie (IRAP), CNRS, CNES, Université de Toulouse, Toulouse, France
| | - S. Madsen
- Jet Propulsion Laboratory, Pasadena, CA USA
| | - E. Mateo-Marti
- Centro de Astrobiología-CSIC-INTA, Torrejón de Ardoz, Spain
| | - J. Medina
- Unidad Asocida UVA-CSIC-CAB, University of Valladolid (UVA), Valladolid, Spain
| | - P.-Y. Meslin
- Institut de Recherche en Astrophysique et Planétologie (IRAP), CNRS, CNES, Université de Toulouse, Toulouse, France
| | - G. Montagnac
- Univ Lyon, ENSL, CNRS, LGL-TPE, Univ Lyon 1, 69007 Lyon, France
| | - A. Moral
- Instituto Nacional de Técnica Aeroespacial, Torrejón de Ardoz, Spain
| | - J. Moros
- University of Malaga (UMA), Málaga, Spain
| | - A. M. Ollila
- Los Alamos National Laboratory, Los Alamos, NM USA
| | - C. Ortega
- Added Value Solutions (AVS), Elgóibar, Spain
| | | | - J. M. Reess
- Laboratoire d’Etudes Spatiales et d’Instrumentation en Astrophysique, Observatoire de Paris-PSL, CNRS, Sorbonne Université, Université de Paris, Meudon, France
| | - S. Robinson
- Los Alamos National Laboratory, Los Alamos, NM USA
| | - J. Rodriguez
- Ingeniería de Sistemas para la Defensa de España S.A. (ISDEFE), Madrid, Spain
| | - J. Saiz
- Unidad Asocida UVA-CSIC-CAB, University of Valladolid (UVA), Valladolid, Spain
| | - J. A. Sanz-Arranz
- Unidad Asocida UVA-CSIC-CAB, University of Valladolid (UVA), Valladolid, Spain
| | - I. Sard
- Added Value Solutions (AVS), Elgóibar, Spain
| | - V. Sautter
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie (IMPMC), CNRS, MNHN, Sorbonne Université, Paris, France
| | - P. Sobron
- SETI Institute, Mountain View, CA USA
| | - M. Toplis
- Observatoire Midi-Pyrénées, Toulouse, France
| | - M. Veneranda
- Unidad Asocida UVA-CSIC-CAB, University of Valladolid (UVA), Valladolid, Spain
| |
Collapse
|
8
|
Drouet C, Henrot P. [Central veinous catheters placement]. Rev Prat 2019; 69:875. [PMID: 32237651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Affiliation(s)
- Clément Drouet
- Service de médecine nucléaire, Centre Georges- François Leclerc, Dijon, France
| | - Philippe Henrot
- Service de radiologie, Institut de cancérologie de Lorraine, Nancy, France
| |
Collapse
|
9
|
Vincent D, Parsopoulou F, Ghanam A, Charignon D, Cichin S, Germenis A, Drouet C. Les angio-œdèmes héréditaires à kinines : nécessité d’une refondation de leur classification, à propos de 4 familles. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
10
|
Brandicourt P, Blanc C, Bonnet L, Béjot Y, Ricolfi F, Drouet C, Moulin T, Thines L. Adult moyamoya angiopathy in Bourgogne-Franche-Comté: Epidemiology, diagnosis and management. Rev Neurol (Paris) 2018; 175:247-251. [PMID: 30447881 DOI: 10.1016/j.neurol.2018.05.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2017] [Revised: 05/06/2018] [Accepted: 05/28/2018] [Indexed: 12/01/2022]
Abstract
INTRODUCTION Moyamoya angiopathy (MMA) is a progressive steno-occlusive disease of the distal internal carotid arteries mainly described in Asia. It induces the development of collateral vascular networks to reduce chronic cerebral hypoperfusion. Symptoms depend on the patient's age in Asia: children are at greater risk of transient or constituted ischemic events, whereas adults are more exposed to hemorrhagic stroke. Data from the literature seem to show that the pattern of MMA in western countries differs from that in Asia. MATERIAL AND METHODS A retrospective study of patients with MMA was conducted in Bourgogne-Franche-Comté (mid-eastern France). Clinical data (symptoms, risk factors, age at diagnosis, number and timing of recurrences, type of treatment) as well as radiological data (angiographic findings, Suzuki's grade) were analyzed. RESULTS Seventeen adult patients (9 men, 53%) were followed at the university hospitals of Besançon and Dijon from 2009 to 2016. Fourteen patients (83%) had bilateral disease. The mean age at diagnosis was 49 years (±16), 83% of the patients were Caucasian and 17% originated from Maghreb. Only 17% of the hemispheres had a hemorrhagic form. Ischemic form was more frequent before diagnosis with transient ischemic attack (24% of patients) and stroke (83% of patients). With medical treatment, 9 patients suffered from stroke recurrence (53% of patients) with an average delay of 22.7±34 months. Three patients (18%) had combined surgical management by encephelo-synangiosis and superficial temporal artery-to-middle cerebral artery (STA-MCA) anastomosis, without symptom recurrence after treatment with an average follow up of 14 months. CONCLUSION MMA remains a rare cerebrovascular disease in Europe and requires multidisciplinary care. Epidemiological analysis showed differences with the Asian population, especially the predominance of ischemic forms in adults.
Collapse
Affiliation(s)
- P Brandicourt
- Service de neurochirurgie, université Bourgogne-Franche-Comté, CHRU de Besançon, 25000 Besançon, France.
| | - C Blanc
- Service de neurologie générale, vasculaire et dégénérative, université Bourgogne-Franche-Comté, CHU de Dijon, 21000 Dijon, France
| | - L Bonnet
- Unité de neurologie vasculaire, université Bourgogne-Franche-Comté, CHRU de Besançon, 25000 Besançon, France
| | - Y Béjot
- Service de neurologie générale, vasculaire et dégénérative, université Bourgogne-Franche-Comté, CHU de Dijon, 21000 Dijon, France
| | - F Ricolfi
- Service de neuroradiologie diagnostique et interventionnelle, université Bourgogne-Franche-Comté, CHU de Dijon, 21000 Dijon, France
| | - C Drouet
- Service de médecine nucléaire, université Bourgogne-Franche-Comté, CHRU de Besançon, 25000 Besançon, France
| | - T Moulin
- Unité de neurologie vasculaire, université Bourgogne-Franche-Comté, CHRU de Besançon, 25000 Besançon, France
| | - L Thines
- Service de neurochirurgie, université Bourgogne-Franche-Comté, CHRU de Besançon, 25000 Besançon, France
| |
Collapse
|
11
|
Belassein A, Drouet C, Morel O, Boulahdour H. [Osteoid osteoma]. Rev Prat 2018; 68:525. [PMID: 30869419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
| | - Clément Drouet
- Service de médecine nucléaire, CHU de Besançon, France
- Université de Bourgogne Franche-Comté, UFR Sciences médicales et pharmaceutiques
- EA 4662 - Nanomedicine Lab, imagery and Therapeutics, UFR Sciences médicales et pharmaceutiques Besançon, France
| | - Olivier Morel
- Service de radiologie, CHI de Vesoul, Vesoul, France
| | - Hatem Boulahdour
- Service de médecine nucléaire, CHU de Besançon, France
- Université de Bourgogne Franche-Comté, UFR Sciences médicales et pharmaceutiques
| |
Collapse
|
12
|
Brandicourt P, Bonnet L, Béjot Y, Drouet C, Moulin T, Thines L. Moya-Moya syndrome after cranial radiation for optic glioma with NF1. Case report and literature review of syndromic cases. Neurochirurgie 2018; 64:63-67. [PMID: 29475609 DOI: 10.1016/j.neuchi.2017.11.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2017] [Revised: 11/18/2017] [Accepted: 11/27/2017] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Moya-Moya angiopathy is a neurovascular disease that predisposes to ischemic or hemorrhagic strokes. It is generated by a steno-occlusion of the terminal portion of the internal carotid arteries, which induces the development of abnormal neovessels in the deep regions of the brain. Some pathologies such as sickle cell disease, Down syndrome or Graves' disease may be associated with Moya-Moya angiopathy. These syndromic forms harbor several differences compared with idiopathic Moya-Moya disease. CASE REPORT We report the case of a young patient who presented with a syndromic form of Moya-Moya angiopathy after cranial radiation therapy for an optic glioma associated with type 1 neurofibromatosis treated by combined revascularization. We discuss the particularities of syndromic forms, in their presentation and management based on a review of the literature. CONCLUSION Many diseases can be associated with Moya-Moya syndrome. Symptomatic patients should undergo surgery, but the risk of postoperative complications appears to be greater than that encountered in patients with non-syndromic Moya-Moya angiopathy.
Collapse
Affiliation(s)
- P Brandicourt
- Service de neurochirurgie, CHRU de Besançon, université Bourgogne-Franche-Comté, 3, boulevard Alexandre-Fleming, 25030 Besançon, France.
| | - L Bonnet
- Unité de neurologie vasculaire, CHRU de Besançon, université Bourgogne-Franche-Comté, 3, boulevard Alexandre-Fleming, 25030 Besançon, France
| | - Y Béjot
- Service de neurologie générale, vasculaire et dégénérative, CHU de Dijon, université Bourgogne-Franche-Comté, 14 rue Paul-Gaffarel, 21000 Dijon, France
| | - C Drouet
- Service de médecine nucléaire, CHRU de Besançon, université Bourgogne-Franche-Comté, 3, boulevard Alexandre-Fleming, 25030 Besançon, France
| | - T Moulin
- Unité de neurologie vasculaire, CHRU de Besançon, université Bourgogne-Franche-Comté, 3, boulevard Alexandre-Fleming, 25030 Besançon, France
| | - L Thines
- Service de neurochirurgie, CHRU de Besançon, université Bourgogne-Franche-Comté, 3, boulevard Alexandre-Fleming, 25030 Besançon, France
| |
Collapse
|
13
|
Drouet C, Macker C, Delabrousse É, Boulahdour H. [Peritoneal tuberculosis]. Rev Prat 2018; 68:60. [PMID: 30840390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- Clément Drouet
- Service de médecine nucléaire, CHU de Besançon, Besançon, France
- Université de Bourgogne Franche-Comté, UFR Sciences médicales et pharmaceutiques, Besançon, France
- EA 4662 - Nanomedicine Lab, imagery and Therapeutics, UFR Sciences médicales et pharmaceutiques, Besançon, France
| | - Caroline Macker
- Service de médecine nucléaire, CHU de Besançon, Besançon, France
| | - Éric Delabrousse
- Université de Bourgogne Franche-Comté, UFR Sciences médicales et pharmaceutiques, Besançon, France
- EA 4662 - Nanomedicine Lab, imagery and Therapeutics, UFR Sciences médicales et pharmaceutiques, Besançon, France
- Service de radiologie, CHU de Besançon, Besançon, France
| | - Hatem Boulahdour
- Service de médecine nucléaire, CHU de Besançon, Besançon, France
- Université de Bourgogne Franche-Comté, UFR Sciences médicales et pharmaceutiques, Besançon, France
- EA 4662 - Nanomedicine Lab, imagery and Therapeutics, UFR Sciences médicales et pharmaceutiques, Besançon, France
| |
Collapse
|
14
|
Ceccaldi M, Jonveaux T, Verger A, Krolak‐Salmon P, Houzard C, Godefroy O, Shields T, Perrotin A, Gismondi R, Bullich S, Jovalekic A, Raffa N, Pasquier F, Semah F, Dubois B, Habert M, Wallon D, Chastan M, Payoux P, Ceccaldi M, Guedj E, Ceccaldi M, Felician O, Didic M, Gueriot C, Koric L, Kletchkova‐Gantchev R, Guedj E, Godefroy O, Andriuta D, Devendeville A, Dupuis D, Binot I, Barbay M, Meyer M, Moullard V, Magnin E, Chamard L, Haffen S, Morel O, Drouet C, Boulahdour H, Goas P, Querellou‐Lefranc S, Sayette V, Cogez J, Branger P, Agostini D, Manrique A, Rouaud O, Bejot Y, Jacquin‐Piques A, Dygai‐Cochet I, Berriolo‐Riedinger A, Moreaud O, Sauvee M, Crépin CG, Pasquier F, Bombois S, Lebouvier T, Mackowiak‐Cordoliani M, Deramecourt V, Rollin‐Sillaire A, Cassagnaud‐Thuillet P, Chen Y, Semah F, Petyt G, Krolak‐Salmon P, Federico D, Danaila KL, Guilhermet Y, Magnier C, Makaroff Z, Rouch I, Xie J, Roubaud C, Coste M, David K, Sarciron A, Waissi AS, Scheiber C, Houzard C, Gabelle‐Deloustal A, Bennys K, Marelli C, Touati L, Mariano‐Goulart D, Verbizier‐Lonjon D, Jonveaux T, Benetos A, Kearney‐Schwartz A, Perret‐Guillaume C, Verger A, Vercelletto M, Boutoleau‐Bretonniere C, Pouclet‐Courtemanche H, Wagemann N, Pallardy A, Hugon J, Paquet C, Dumurgier J, Millet P, Queneau M, Dubois B, Epelbaum S, Levy M, Habert M, Novella J, Jaidi Y, Papathanassiou D, Morland D, Belliard S, Salmon A, Lejeune F, Hannequin D, Wallon D, Martinaud O, Zarea A, Chastan M, Pariente J, Thalamas C, Galitzky‐Gerber M, Tricoire Ricard A, Calvas F, Rigal E, Payoux P, Hitzel A, Delrieu J, Ousset P, Lala F, Sastre‐Hengan N, Stephens A, Guedj E. Added value of
18
F‐florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study. Alzheimers Dement 2017; 14:293-305. [DOI: 10.1016/j.jalz.2017.09.009] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2017] [Revised: 08/29/2017] [Accepted: 09/06/2017] [Indexed: 11/25/2022]
Affiliation(s)
- Mathieu Ceccaldi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Thérèse Jonveaux
- Geriatric Department CHRU de Nancy–Hôpital Brabois Vandoeuvre‐les‐Nancy France
| | - Antoine Verger
- INSERM U947 Unité d'Imagerie Adaptative Diagnostique et Interventionnelle Nancy France
| | - Pierre Krolak‐Salmon
- Clinical and Research Memory Center of Lyon Hospices civils de Lyon, Université Claude Bernard Lyon 1 Inserm 1028 Lyon France
| | | | - Olivier Godefroy
- Neurology Department CHU Amiens Picardie–Hôpital Sud Amiens France
| | - Trevor Shields
- Nuclear Medicine Department CHU Amiens Picardie–Hôpital Sud Amiens France
| | - Audrey Perrotin
- Piramal Imaging Clinical Research and Development Berlin Germany
| | | | - Santiago Bullich
- AP‐HP–Hôpital Pitié Salpétrière Memory and Alzheimer Disease Institute IM2A Paris France
| | - Aleksandar Jovalekic
- Laboratoire d'Imagerie Biomédicale Sorbonne Universités, UPMC Univ Paris 06, Inserm U 1146, CNRS UMR 7371 Paris France
| | - Nicola Raffa
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Florence Pasquier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Franck Semah
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Bruno Dubois
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marie‐Odile Habert
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - David Wallon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Chastan
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pierre Payoux
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Ceccaldi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Eric Guedj
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Ceccaldi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Felician
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mira Didic
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Claude Gueriot
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Lejla Koric
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Radka Kletchkova‐Gantchev
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Eric Guedj
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Godefroy
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Daniela Andriuta
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Agnès Devendeville
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Diane Dupuis
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Ingrid Binot
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mélanie Barbay
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marc‐Etienne Meyer
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Véronique Moullard
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Eloi Magnin
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Ludivine Chamard
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Sophie Haffen
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Morel
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Clément Drouet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Hatem Boulahdour
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Philippe Goas
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Solène Querellou‐Lefranc
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Vincent Sayette
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Julien Cogez
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pierre Branger
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Denis Agostini
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Alain Manrique
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Rouaud
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Yannick Bejot
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Agnès Jacquin‐Piques
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Inna Dygai‐Cochet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Alina Berriolo‐Riedinger
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Moreaud
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathilde Sauvee
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Céline Gallazzani Crépin
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Florence Pasquier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Stéphanie Bombois
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Thibaud Lebouvier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marie‐Anne Mackowiak‐Cordoliani
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Vincent Deramecourt
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Adeline Rollin‐Sillaire
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pascaline Cassagnaud‐Thuillet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Yaohua Chen
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Franck Semah
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Grégory Petyt
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pierre Krolak‐Salmon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Denis Federico
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Keren Liora Danaila
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Yves Guilhermet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Christophe Magnier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Zaza Makaroff
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Isabelle Rouch
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Jing Xie
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Caroline Roubaud
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marie‐Hélène Coste
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Kenny David
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Alain Sarciron
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Aziza Sediq Waissi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Christian Scheiber
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Claire Houzard
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Audrey Gabelle‐Deloustal
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Karim Bennys
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Cecilia Marelli
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Lynda Touati
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Denis Mariano‐Goulart
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Delphine Verbizier‐Lonjon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Thérèse Jonveaux
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Athanase Benetos
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Anna Kearney‐Schwartz
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Christine Perret‐Guillaume
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Antoine Verger
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Martine Vercelletto
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Claire Boutoleau‐Bretonniere
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Hélène Pouclet‐Courtemanche
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Nathalie Wagemann
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Amandine Pallardy
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Jacques Hugon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Claire Paquet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Julien Dumurgier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pascal Millet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Queneau
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Bruno Dubois
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Stéphane Epelbaum
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marcel Levy
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | | | - Jean‐Luc Novella
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Yacine Jaidi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Dimitri Papathanassiou
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | | | - Serge Belliard
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Anne Salmon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Florence Lejeune
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Didier Hannequin
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - David Wallon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Martinaud
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Aline Zarea
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Chastan
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | | | - Claire Thalamas
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | | | | | - Fabienne Calvas
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Emilie Rigal
- ToNIC, Toulouse NeuroImaging Center Université de Toulouse, Inserm, UPS Toulouse France
| | - Pierre Payoux
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Anne Hitzel
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Julien Delrieu
- Neurology Department CHU de Rouen–Hôpital Charles Nicolle Rouen France
| | - Pierre‐Jean Ousset
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Françoise Lala
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Nathalie Sastre‐Hengan
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Andrew Stephens
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Eric Guedj
- AP‐HM–Hôpital de la Timone, Nuclear Medicine Department Aix‐Marseille University, CERIMED, CNRS, INT, Institut de Neurosciences de la Timone Marseille France
| | | |
Collapse
|
15
|
Chetouani A, Perrin M, Drouet C, Marie PY, Verger A. Aneurysmal angiosarcoma associated with vascular graft revealed by 18F-FDG-PET imaging. Radiol Case Rep 2017; 12:413-415. [PMID: 28491200 PMCID: PMC5417621 DOI: 10.1016/j.radcr.2016.12.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2016] [Revised: 12/05/2016] [Accepted: 12/19/2016] [Indexed: 11/30/2022] Open
Abstract
We report a rare case of vascular graft-associated aneurysmal angiosarcoma by 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET). An 81-year-old male patient, with a prior history of graft interposition 1 year previously, was referred to 18F-FDG-PET because of an inflammatory syndrome of unknown origin. FDG-PET images revealed a particular pattern of intense circular uptake within the arterial wall (SUVmax = 10) in a popliteal aneurysm and, additionally, a large hypermetabolic mass centered by the graft. Remote hypermetabolisms in lung nodules and pleural thickenings were also detected. The diagnosis of angiosarcoma was ascertained through histopathological analysis of surgical samples. Development of an aneurysmal angiosarcoma at the site of a vascular graft is a rare entity, often misdiagnosed. 18F-FDG-PET appears to be useful in its detection with a PET pattern of intense circular uptake within the arterial wall. Such finding should lead to the search for distant metastasis.
Collapse
Affiliation(s)
- Ahmed Chetouani
- Department of Nuclear Medicine, CHRU-Nancy, rue du Morvan, Nancy F-54000, France
| | - Mathieu Perrin
- Department of Nuclear Medicine, CHRU-Nancy, rue du Morvan, Nancy F-54000, France
| | - Clément Drouet
- Department of Nuclear Medicine, CHRU-Besançon, Besançon F-25000, France
| | - Pierre-Yves Marie
- Department of Nuclear Medicine, CHRU-Nancy, rue du Morvan, Nancy F-54000, France.,Nancyclotep Platform Imaging, rue du Morvan, Nancy F-54000, France
| | - Antoine Verger
- Department of Nuclear Medicine, CHRU-Nancy, rue du Morvan, Nancy F-54000, France.,Nancyclotep Platform Imaging, rue du Morvan, Nancy F-54000, France
| |
Collapse
|
16
|
Drouet C, Morel O, Verger A, Guedj E, Boulahdour H. FDG Brain PET/CT Revealing Bilateral Thalamostriatal Activation During a Symptomatic Episode in a Patient With Kleine-Levin Syndrome. Clin Nucl Med 2017; 42:e261-e262. [DOI: 10.1097/rlu.0000000000001616] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Maciejewski M, Ponard D, Humeau H, Sarre M, Drouet C, Martin L. Devenir des patientes ayant présenté un angio-œdème bradykininique sous pilule estrogénique. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
Ghannam A, Sellier P, Defendi F, Favier B, Charignon D, López-Lera A, López-Trascasa M, Ponard D, Drouet C. C1 inhibitor function using contact-phase proteases as target: evaluation of an innovative assay. Allergy 2015; 70:1103-11. [PMID: 26010015 DOI: 10.1111/all.12657] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/20/2015] [Indexed: 12/13/2022]
Abstract
BACKGROUND Controlling prekallikrein activation by C1 inhibitor (C1Inh) represents the most essential mechanism for angioedema patient protection. C1Inh function in the plasma is usually measured based on the residual activity of the C1s protease not involved in the pathological process. We have hereby proposed an alternative enzymatic measurement of C1Inh function based on contact-phase activation and correlation with angioedema diagnostic requirements. METHODS The contact phase was reconstituted using the purified components, with C1Inh standard or plasma sample. The kinetics of the amidase activity were monitored using Pro-Phe-Arg-pNA, independently of alpha2-macroglobulin. We prevented any interference from a possible high plasma kininogenase activity by preincubating the samples with protease inhibitor. Receiver operating characteristics (ROC) were used to calculate the assay's diagnostic performance. RESULTS The calibration curve was built using C1Inh standard (threshold limit 0.10 × 10(-3) U, i.e., 0.2 pmol), and C1Inh function was quantified in the sample, with a reference interval established based on healthy individuals (n = 281; men: 0.61-1.10 U/ml, median: 0.85 U/ml; women: 0.42-1.08 U/ml, median: 0.74 U/ml). The median values of female donors were lower than those of the others due to estrogen, yet C1Inh function remained within the reference interval. The ROC curve calculation provided the following optimum diagnostic cutoff values: women 0.36 U/ml (area under curve [AUC]: 0.99; sensitivity: 93.48%; specificity: 99.37%); and men 0.61 U/ml (AUC: 1; sensitivity: 100.0%; specificity: 100.0%). CONCLUSION The performance outcome provided features suitable for angioedema diagnostic or follow-up. Established by means of the kinin formation process, this assay should be preferred over the method based on a C1s protease target.
Collapse
Affiliation(s)
- A. Ghannam
- GREPI/AGIM CNRS FRE 3405; Université Joseph Fourier; Grenoble France
- KininX SAS; Grenoble France
| | - P. Sellier
- GREPI/AGIM CNRS FRE 3405; Université Joseph Fourier; Grenoble France
- KininX SAS; Grenoble France
| | - F. Defendi
- GREPI/AGIM CNRS FRE 3405; Université Joseph Fourier; Grenoble France
- Centre de Référence des Angioedèmes CREAK; CHU Grenoble; Grenoble France
| | - B. Favier
- GREPI/AGIM CNRS FRE 3405; Université Joseph Fourier; Grenoble France
| | - D. Charignon
- GREPI/AGIM CNRS FRE 3405; Université Joseph Fourier; Grenoble France
- Centre de Référence des Angioedèmes CREAK; CHU Grenoble; Grenoble France
| | - A. López-Lera
- Unidad de Inmunología; Hospital Universitario La Paz/IdiPAZ; Madrid Spain
- Centro de Investigación Biomédica en Red (CIBERER U-754); Madrid Spain
| | - M. López-Trascasa
- Unidad de Inmunología; Hospital Universitario La Paz/IdiPAZ; Madrid Spain
- Centro de Investigación Biomédica en Red (CIBERER U-754); Madrid Spain
| | - D. Ponard
- Centre de Référence des Angioedèmes CREAK; CHU Grenoble; Grenoble France
| | - C. Drouet
- GREPI/AGIM CNRS FRE 3405; Université Joseph Fourier; Grenoble France
- Centre de Référence des Angioedèmes CREAK; CHU Grenoble; Grenoble France
| |
Collapse
|
19
|
Defendi F, Charignon D, Ghannam A, Ponard D, Drouet C. [Biological investigation of kinin-mediated angioedema]. Ann Dermatol Venereol 2015; 142:163-9. [PMID: 25683013 DOI: 10.1016/j.annder.2015.01.018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2014] [Revised: 11/21/2014] [Accepted: 01/06/2015] [Indexed: 11/15/2022]
Abstract
Kinin-mediated angioedema results from accumulation of kinins, vasoactive and vasopermeant peptides, on the vascular endothelium. The disease is characterized by sudden episodes of swelling in the subcutaneous and submucosal tissues; the edema may occur spontaneously or it may be precipitated by triggering factors such as physical or emotional stress, or certain medicines. The characterization of kinin formation and catabolism systems helps improve knowledge of the aetiopathogenic mechanisms involved and provides the basis for classification of kinin-mediated angioedema conditions; thus, we may distinguish between angioedema with C1 inhibitor deficiency, whether inherited or acquired, and angioedema with normal C1 inhibitor activity, associated with increased kinin-forming activity or deficiency in kinin catabolism enzymes. In support of the clinical diagnosis, the physician may request laboratory investigation for a functional and molecular definition of the disease. Laboratory diagnosis is based on the characterization of: (1) kinin production control by C1 inhibitor investigation (function, antigen levels and circulating species); (2) kinin production (kininogenase activity, kininogen cleavage species); and (3) kinin catabolism enzymes (aminopeptidase P, carboxypeptidase N, angiotensin-I converting enzyme and dipeptidyl peptidase IV). An abnormal biological phenotype is supported by examination of susceptibility genes (SERPING1, F12 and XPNPEP2) and mutation segregation in the families.
Collapse
Affiliation(s)
- F Defendi
- Exploration fonctionnelle de l'angiœdème, CHU Grenoble, CS 10217, 38043 Grenoble, France; Université Joseph Fourier, GREPI/AGIM CNRS FRE 3405, 38043 Grenoble cedex 9, France.
| | - D Charignon
- Exploration fonctionnelle de l'angiœdème, CHU Grenoble, CS 10217, 38043 Grenoble, France; Université Joseph Fourier, GREPI/AGIM CNRS FRE 3405, 38043 Grenoble cedex 9, France
| | - A Ghannam
- Exploration fonctionnelle de l'angiœdème, CHU Grenoble, CS 10217, 38043 Grenoble, France; Université Joseph Fourier, GREPI/AGIM CNRS FRE 3405, 38043 Grenoble cedex 9, France
| | - D Ponard
- Laboratoire d'immunologie, CHU Grenoble, CS 10217, 38043 Grenoble, France
| | - C Drouet
- Exploration fonctionnelle de l'angiœdème, CHU Grenoble, CS 10217, 38043 Grenoble, France; Université Joseph Fourier, GREPI/AGIM CNRS FRE 3405, 38043 Grenoble cedex 9, France
| |
Collapse
|
20
|
Charignon D, Ghannam A, Defendi F, Ponard D, Monnier N, López Trascasa M, Launay D, Caballero T, Djenouhat K, Fain O, Cichon S, Martin L, Drouet C. Hereditary angioedema with F12 mutation: factors modifying the clinical phenotype. Allergy 2014; 69:1659-65. [PMID: 25134986 DOI: 10.1111/all.12515] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/12/2014] [Indexed: 11/27/2022]
Abstract
BACKGROUND Hereditary angioedema (HAE) with normal C1 inhibitor (C1Inh) associated with the c.983C>A and c.983C>G mutations of the F12 gene (FXII-HAE) is a rare condition, and presents with highly variable clinical expression. On the basis of data gathered from a large carrier cohort, we assessed the modifiers affecting the clinical phenotype. METHODS We analyzed clinical and biological data recorded from 118 mutation carriers (80 symptomatic and 38 asymptomatic), 58 noncarrier relatives from 40 families, and 200 healthy donors. Disease severity was scored in relation to frequency and location of edema, as well as age at disease onset. To predict FXII-HAE disease severity, we analyzed the biological phenotype [C1Inh, C4, spontaneous amidase, angiotensin-I-converting enzyme (ACE), aminopeptidase P (APP), and carboxypeptidase N/M (CPN)] by means of logistic regression (Akaike information criterion) and odds ratio (OR). RESULTS Meaningful variables contributed to FXII-HAE, with the kinin catabolism enzymes ACE and CPN exhibiting a significant inverse relationship with disease severity (OR = 0.36, 95% CI 0.23-0.59, P < 0.001; OR = 0.58, 95% CI 0.36-0.91, P < 0.05, respectively). CPN activities were 37.5 (28.5-41.3) nmol/ml/min and 38.5 (32.8-45.6) for FXII-HAE asymptomatic and symptomatic carriers, respectively, and 37.9 (30.5-43.7) nmol/ml/min for noncarriers. Angiotensin-I-converting enzyme activities were 58 (44-76) and 49 (35-59) nmol/ml/min for FXII-HAE asymptomatic and symptomatic carriers, respectively, and 56 (49-66) nmol/ml/min for noncarriers. CONCLUSIONS The FXII-HAE is associated with modifiers, for example kinin catabolism enzymes, ACE and CPN, different from those recognized in HAE with C1Inh deficiency.
Collapse
Affiliation(s)
- D. Charignon
- CREAK; Centre de Référence des Angioedèmes; Grenoble France
- GREPI/AGIM CNRS FRE 3405; Université Joseph Fourier; Grenoble France
| | - A. Ghannam
- CREAK; Centre de Référence des Angioedèmes; Grenoble France
- GREPI/AGIM CNRS FRE 3405; Université Joseph Fourier; Grenoble France
| | - F. Defendi
- CREAK; Centre de Référence des Angioedèmes; Grenoble France
- GREPI/AGIM CNRS FRE 3405; Université Joseph Fourier; Grenoble France
| | - D. Ponard
- CREAK; Centre de Référence des Angioedèmes; Grenoble France
| | - N. Monnier
- CREAK; Centre de Référence des Angioedèmes; Grenoble France
| | - M. López Trascasa
- Institute for Health Research (IdiPaz); Hospital Universitario La Paz; Madrid Spain
- Biomedical Research Network on Rare Diseases-U754 (CIBERER); Madrid Spain
| | - D. Launay
- CREAK; Centre de Référence des Angioedèmes; Grenoble France
- Département de Médecine Interne; Université du Droit et de la Santé Lille 2; Lille France
| | - T. Caballero
- Institute for Health Research (IdiPaz); Hospital Universitario La Paz; Madrid Spain
- Biomedical Research Network on Rare Diseases-U754 (CIBERER); Madrid Spain
| | - K. Djenouhat
- Département d'Immunologie; Institut Pasteur; Alger Algeria
| | - O. Fain
- CREAK; Centre de Référence des Angioedèmes; Grenoble France
- Département de Médecine Interne; Université Paris XIII; Bondy France
| | - S. Cichon
- Institute für Humangenetics; Universität Bonn; Bonn Germany
- Departement Biomedizin; Universität Basel; Basel Switzerland
| | - L. Martin
- CREAK; Centre de Référence des Angioedèmes; Grenoble France
- Département de Dermatologie; L'UNAM Université; Hôpital d'Angers; Angers France
| | - C. Drouet
- CREAK; Centre de Référence des Angioedèmes; Grenoble France
- GREPI/AGIM CNRS FRE 3405; Université Joseph Fourier; Grenoble France
| |
Collapse
|
21
|
Baillet A, Trocmé C, Marotte H, Soubrier M, Tébib J, Thomas T, Miossec P, Pellot-Prades B, Grange L, Toussaint B, Juvin R, Morel F, Drouet C, Gaudin P. THU0154 Biomarker Sets PREDICT Therapeutic Response to Tnf-Inhibitors in Rheumatoid Arthritis and Spondyloarthritis Patients: A Theragnostic Approach in A Multicenter Cohort: Table 1. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5750] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
22
|
Grunenwald A, Keyser C, Sautereau AM, Crubézy E, Ludes B, Drouet C. Novel contribution on the diagenetic physicochemical features of bone and teeth minerals, as substrates for ancient DNA typing. Anal Bioanal Chem 2014; 406:4691-704. [DOI: 10.1007/s00216-014-7863-z] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2014] [Revised: 04/25/2014] [Accepted: 04/28/2014] [Indexed: 11/28/2022]
|
23
|
Beaudouin E, Defendi F, Picaud J, Drouet C, Ponard D, Moneret-Vautrin DA. Iatrogenic angioedema associated with ACEi, sitagliptin, and deficiency of 3 enzymes catabolizing bradykinin. Eur Ann Allergy Clin Immunol 2014; 46:119-122. [PMID: 24853572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
New concepts of idiopathic and iatrogenic angioedema underline the role of bradykinin, and the importance of catabolizing enzymes. A case is described of Angiotensin converting enzyme inhibitor (ACEi) and sitagliptin induced angioedema, where AO attacks decreased after the withdrawal of lisinopril but resolved only after the withdrawal of sitagliptin, an inhibitor of dipeptylpeptidase IV. ACE, aminopeptidase P and carboxypeptidase N were decreased down to 17%, 42%, 64% of median references values, and remained low one year after the interruption of these drugs: 56%, 28% and 50%, respectively. The combined deficiency of APP and CPN might enhance the inhibiting effect of the DPP IV inhibitor. The fact that this triple deficiency remained latent before and after the treatment indicates that searching for latent enzyme deficiencies should be carried out when there is intention to treat with a combination of drugs interfering with the bradykinin metabolism.
Collapse
Affiliation(s)
- E Beaudouin
- Service d'Allergologie, Centre Hospitalier E Durkheim, Epinal, France
| | - F Defendi
- French Reference Center for Angioedema, CREAK, Grenoble, France. Université Joseph Fourier, GREPI/AGIM CNRS FRE 3405, Grenoble, France
| | - J Picaud
- Service d'Allergologie, Centre Hospitalier E Durkheim, Epinal, France
| | - C Drouet
- French Reference Center for Angioedema, CREAK, Grenoble, France. Université Joseph Fourier, GREPI/AGIM CNRS FRE 3405, Grenoble, France
| | - D Ponard
- Laboratoire d'Immunologie IBP, Grenoble, France
| | - D A Moneret-Vautrin
- Service d'Allergologie, Centre Hospitalier E Durkheim, Epinal, France. Université de Lorraine Nancy, France
| |
Collapse
|
24
|
Tourbin M, Al-Kattan A, Drouet C. Study on the stability of suspensions based on biomimetic apatites aimed at biomedical applications. POWDER TECHNOL 2014. [DOI: 10.1016/j.powtec.2013.08.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
25
|
Defendi F, Charignon D, Ghannam A, Ponard D, Nicolie B, Fain O, Martin L, Drouet C. Intérêt de l’étude du métabolisme de la bradykinine (BK) pour la prise en charge des angioedèmes. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Liszewski M, Kolev M, Le Friec G, Leung M, Bertram P, Pickering M, Drouet C, Meri S, Arstila T, Pekkarinen P, Reinheckel T, Cordoba SRD, Afzali B, Atkinson J, Kemper C. Evidence for intracellular complement activation vital to Th1 immunity. Mol Immunol 2013. [DOI: 10.1016/j.molimm.2013.05.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Dessart P, Humeau H, Nicolie B, Ponard D, Drouet C, Martin L. Proportion relative des différents types d’angio-oedemes bradykiniques (AOBK) dans une population consultant en centre de référence. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
28
|
Sarre M, Dessart P, Humeau H, Nicolie B, Ponard D, Drouet C, Martin L. Proportion relative des différents types d’angio-œdèmes bradykiniques dans une population pédiatrique consultant en centre de référence. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Ghannam A, Defendi F, Favier B, Ponard D, Drouet C. C1 inhibitor function with kinin forming enzymes as target: Evaluation of a novel assay. Mol Immunol 2013. [DOI: 10.1016/j.molimm.2013.05.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
30
|
Ghannam A, Kemper C, Drouet C. Th1 induction requires T cell-derived complement C3a and CD46 activation. Mol Immunol 2013. [DOI: 10.1016/j.molimm.2013.05.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
31
|
Gayet S, Martinez S, Jean-Pastor MJ, Monnier N, Drouet C, Harlé JR. Œdème bradykinique induit par la prise d’inhibiteur de la dipeptidylpeptidase IV. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.03.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
32
|
Millot I, Plancade D, Hosotte M, Landy C, Nadaud J, Ragot C, Graffin B, Drouet C, Kanny G. Treatment of a life-threatening laryngeal bradykinin angio-oedema precipitated by dipeptidylpeptidase-4 inhibitor and angiotensin-I converting enzyme inhibitor with prothrombin complex concentrates. Br J Anaesth 2013; 109:827-9. [PMID: 23066003 DOI: 10.1093/bja/aes371] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Poutord C, Drouet M, Delva R, Dessart P, Drouet C, Martin L. Angio-œdèmes bradykiniques (AOBK) attribués à des anti-androgènes chez l’homme : deux cas. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
34
|
Giard C, Nicolie B, Drouet M, Lefebvre-Lacoeuille C, Le Sellin J, Bonneau JC, Maillard H, Rénier G, Cichon S, Ponard D, Drouet C, Martin L. Angio-oedema induced by oestrogen contraceptives is mediated by bradykinin and is frequently associated with urticaria. Dermatology 2012; 225:62-9. [PMID: 22922353 DOI: 10.1159/000340029] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2012] [Accepted: 06/04/2012] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND Hereditary C1-inhibitor (C1-Inh) deficiency is associated with 'bradykinin-mediated angio-oedema' (BK-AO) and is believed not to be associated with urticaria. Acquired AO has been related to oestrogen contraceptives. OBJECTIVE To demonstrate that AO precipitated by oestrogens and characterized by nonfunctional C1-Inh is mediated by BK and to evaluate the occurrence of urticaria in these patients. METHODS A retrospective evaluation of patients referred for AO related to oestrogen was undertaken. Circulating C1-Inh, high molecular weight kininogen (HK) and enzymes involved in the metabolism of bradykinin were investigated. RESULTS Fifteen patients were included. HK cleavage concurrent to oestrogen intake was demonstrated in 10 patients with available plasma. Eight patients reported recurrent or chronic urticaria. Discontinuation of the contraceptive resulted in a return to native C1-Inh and HK in all cases studied and to normal kininogenase activity in all but one. The clinical manifestations completely disappeared in 6 patients and improved in 7 after the withdrawal of oestrogen. CONCLUSION Patients display extensive cleavage of HK in the plasma, which supports that AO precipitated by oestrogen contraception is BK-mediated. Recurrent urticaria may have been underestimated in this context. The presence of recurrent urticaria should not systematically rule out the diagnosis of BK-AO when the history is suggestive.
Collapse
Affiliation(s)
- C Giard
- Department of Dermatology, L’UNAM University, Angers Hospital, Angers, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Drouet C, Brunot B, Karcher G. [Neurogenic paraosteoarthropathy]. Rev Prat 2012; 62:168. [PMID: 22408852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Affiliation(s)
- Clément Drouet
- Service de médecine nucléaire, SSM hôpital de Freyming-Merlebach, 57800 Freyming-Merlebach
| | | | | |
Collapse
|
36
|
Zuraw BL, Bork K, Banerji A, Christiansen SC, Castaldo A, Kaplan A, Riedl M, Kirkpatrick C, Magerl M, Drouet C, Cacardi M. Hereditary angioedema with normal C1 inhibitor function: Consensus of an international expert panel. Allergy Asthma Proc 2012. [DOI: 10.2500/aap2012.33.3627] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
37
|
Drouet C, Khoy K, Masson D, Bardy B, Giannoli C, Dubois V. [The immunological conflict in the transfusion-related acute lung injury or TRALI]. Transfus Clin Biol 2011; 18:224-9. [PMID: 21470890 DOI: 10.1016/j.tracli.2011.02.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2011] [Accepted: 02/12/2011] [Indexed: 10/18/2022]
Abstract
Despite its underrated incidence, transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related morbidity and mortality worldwide. The pulmonary edema in TRALI occurs in the course of the transfusion of apheresis products or erythrocyte concentrates. Its pathogenesis is attributed to the infusion of donor antibodies that recognize leucocyte antigens in the transfused host, with subsequent sequestration of leucocytes in the pulmonary vessels. It is also associated with the passive transfer of lipids and other biological response modifiers that accumulate during the storage or processing of blood components. The innate immunity and inflammatory kinins are key components. The knowledge of its etiopathogenesis must come into play for improving prevention and diagnosis and for application of adapted care of the patient.
Collapse
Affiliation(s)
- C Drouet
- GREPI/AGIM CNRS FRE 3405, CHU de Grenoble, BP 217, 38043 Grenoble, France.
| | | | | | | | | | | |
Collapse
|
38
|
Bygum A, Fagerberg CR, Ponard D, Monnier N, Lunardi J, Drouet C. Mutational spectrum and phenotypes in Danish families with hereditary angioedema because of C1 inhibitor deficiency. Allergy 2011; 66:76-84. [PMID: 20804470 DOI: 10.1111/j.1398-9995.2010.02456.x] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Hereditary angioedema (HAE), type I and II, is an autosomal dominant disease with deficiency of functional C1 inhibitor protein causing episodic swellings of skin, mucosa and viscera. HAE is a genetically heterogeneous disease with more than 200 different mutations in the SERPING1 gene. A genotype-phenotype relationship does not seem to exist in HAE, although the polymorphism c.-21T>C of exon 2 has been reported to be associated with a more severe phenotype. We aimed to establish the mutational spectrum of C1 inhibitor deficiency in Denmark and investigate the possible disease-aggravating effect of the c.-21T>C polymorphism. METHODS Hereditary angioedema was diagnosed based on clinical features and C1 inhibitor deficiency. A general severity score ranging from 0 to 10 was developed based on age at disease onset, clinical manifestations and treatment experiences. SERPING1 gene investigation was performed by exon sequencing followed by multiplex ligation-dependent probe amplification genomic rearrangement analysis in all known Danish HAE families. RESULTS Fifty-nine patients with HAE from 26 families were included in this study. The mean disease severity score was 7.12 [1-10], and the mean C1 inhibitor function was 26% [20-46%]. The sensitivity of the mutational screening was 96%, and 13 new mutations were found in this Danish patient cohort. Nine patients (15%) carried the c.-21T>C polymorphism, but they didn't have a more severe phenotype. CONCLUSION Thirteen new mutations were identified in the Danish HAE population. No correlation between the c.-21T>C polymorphism, the biochemical values of C1 inhibitor function and the clinical severity score was found.
Collapse
Affiliation(s)
- A Bygum
- Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.
| | | | | | | | | | | |
Collapse
|
39
|
Vitrat-Hincky V, Gompel A, Dumestre-Perard C, Boccon-Gibod I, Drouet C, Cesbron JY, Lunardi J, Massot C, Bouillet L. Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy 2010; 65:1331-6. [PMID: 20384613 DOI: 10.1111/j.1398-9995.2010.02368.x] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Hereditary angio-oedema (HAE) has been associated with C1inhibitor deficiency. The first cases of type III HAE were described in patients with normal C1Inh antigenic protein level and function and normal C4 levels in 2000. This finding has been reported mostly in women with a family history and may be influenced by exogenous oestrogen exposure. OBJECTIVES The purpose of this article is to describe the clinical, biological and genetic characteristics of a French population suffering from type III HAE. PATIENTS AND METHODS We conducted a retrospective analysis of angio-oedema (AE) cases seen in the National Reference Centre of AE between 2000 and 2009. RESULTS We found 26 patients (from 15 unrelated families) with type III HAE. All but four were women and presented with typical AE attacks, exacerbated by pregnancy or oral contraceptives containing oestrogens (OC). We also found that 54.5% of women were worsened with oestrogen and 23% were oestrogen dependent. All patients improved on long-term prophylactic tranexamic acid treatment; some acute attacks improved with C1Inh concentrate infusion. All of the patients had normal C1Inh and C4 levels. C1Inh function was also normal, except in women receiving OC or during a pregnancy: transient, moderately low levels (32-74% of the normal range) were found in 18 patients tested (67%). No SERPING1 gene mutation was found. Six patients from three unrelated families were heterozygous for an F12 gene variant. CONCLUSION Diagnosis of type III HAE should be based on clinical (typical attacks, often hormonally influenced), laboratory (normal C1Inh antigenic protein) and genetic (F12 gene mutation) evidence.
Collapse
Affiliation(s)
- V Vitrat-Hincky
- Internal Medicine Department, University Hospital of Grenoble, Grenoble, France
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Affiliation(s)
- A Du-Thanh
- Service de Dermatologie-allergologie, CHU Saint Eloi, 80 avenue Augustin Fliche, Montpellier Cedex 5, France.
| | | | | | | |
Collapse
|
41
|
Bouillet L, Boccon-Gibod I, Ponard D, Drouet C, Cesbron JY, Dumestre-Perard C, Monnier N, Lunardi J, Massot C. Prise en charge des grossesses chez les femmes ayant un angiœdème héréditaire de type III. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.03.425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
42
|
Morisset M, Drouet C, Beaudouin E, Luyasu S, Codreanu F, Petit N, Cordebar V, Renaudin JM, Moneret-Vautrin DA, Kanny G. Les anti-leucotriènes : un nouveau traitement de l’angiœdème récidivant idiopathique ? À propos de 25 cas traités par Montelukast. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.03.427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
43
|
Bouillet L, Boccon-Gibod I, Ponard D, Drouet C, Cesbron JY, Dumestre-Perard C, Monnier N, Lunardi J, Massot C, Gompel A. L’icatibant (antagoniste des récepteurs B2 de la Bradykinine) est efficace dans le traitement des angioedèmes héréditaires de type III. Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.10.375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
44
|
Affiliation(s)
- C Rey
- University of Toulouse, CIRIMAT, ENSIACET, 118 Route de Narbonne 31077, Toulouse Cedex 04, France
| | | | | | | |
Collapse
|
45
|
|
46
|
Chumpitazi BFF, Bouillet L, Drouet MT, Kuhn L, Garin J, Zarski JP, Drouet C. Biological autoimmunity screening in hepatitis C patients by anti-HepG2 lysate and anti-heat shock protein 70.1 autoantibodies. Eur J Clin Microbiol Infect Dis 2008; 28:137-46. [PMID: 18696130 DOI: 10.1007/s10096-008-0599-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2008] [Accepted: 07/07/2008] [Indexed: 12/16/2022]
Abstract
Viruses require viral and cellular chaperones during their life cycle and interactions of these molecules with the immune system are probable during the infection. Thus, an anti-chaperone antibody response has been firstly investigated in hepatitis C patients in this paper. A HepG2-lysate antigen (90, 79, 72, 70, 62, 54 and 48 kDa) was assayed in sera from 59 (19F/40M) chronic hepatitis C patients without cirrhosis before therapy. Forty of them were positive for anti-HepG2 lysate antigen antibodies and this test may evaluate biological autoimmunity. Hsp70.1, Hsp90 and calreticulin levels were significantly higher in this antigen than in a control HepG2 antigen. Secondly, Hsp70.1 was identified as Hsp 70 kDa protein-1 by proteomic analysis and studied as a possible antibody target. Fourteen out of 59 patients were positive for anti-Hsp70.1 antibodies that were inversely correlated with alanine aminotransferase levels, the Metavir activity index and viraemia. Finally, for comparative purposes, 50 sera from systemic lupus erythematosus (SLE) patients have been tested: eight and 41 of them were positive for anti-Hsp70.1 and anti-HepG2 lysate antigen antibodies, respectively. Therefore, anti-Hsp70.1 autoantibodies may be produced and can partially lead to biological autoimmunity in chronic hepatitis C patients.
Collapse
Affiliation(s)
- B F F Chumpitazi
- Laboratoire d'Immunologie du Département de Biologie et Pathologie de la Cellule, CHU de Grenoble, Hôpital Michalon, BP 217X, 38043, Grenoble, France.
| | | | | | | | | | | | | |
Collapse
|
47
|
Bouillet L, Ponard D, Rousset H, Cichon S, Drouet C. A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Br J Dermatol 2007; 156:1063-5. [PMID: 17381464 DOI: 10.1111/j.1365-2133.2007.07778.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
Bouillet L, Chumpitazi B, Miossec P, Zarski JP, Drouet C. Un rôle des Heat Shock Protéines dans l'auto-immunité associée au VHC? Rev Med Interne 2006. [DOI: 10.1016/j.revmed.2006.10.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
49
|
Drouet C, Ponard D, Bouillet L. [Iatrogenic angioedema due to estrogen, angiotensin conversion enzyme inhibitors, angiotensin receptor antagonists and dialysis membranes]. Rev Med Interne 2006; 27 Suppl 2:S76-9. [PMID: 16697083 DOI: 10.1016/j.revmed.2006.03.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2006] [Accepted: 04/07/2006] [Indexed: 11/16/2022]
Affiliation(s)
- C Drouet
- Laboratoire d'immunologie et clinique de médecine interne, CHU de Grenoble, hôpital Sud, BP 338, 38434 Echirolles, France.
| | | | | |
Collapse
|
50
|
Abstract
INTRODUCTION Antimitochondrial type M5 antibodies (AMA-M5) are among the immunological abnormalities associated with Sneddon syndrome. CASE A 45 year-old woman, hospitalized for diplopia and with a 20-year history of obstetrical accidents, internuclear ophthalmoplegia and livedo, was diagnosed with Sneddon syndrome associated with primary antiphospholipid syndrome (APS) aggravated by the presence of AMA-M5. DISCUSSION AMA-M5 are immunological markers of APS to the same extent as antiphospholipid antibodies. This case demonstrates the interest of screening for AMA-M5 in cases of strong clinical suspicion of APS when the anticoagulant lupus test is normal and no anti-cardiolipin, anti-b2 glycoprotein I or antiprothrombin antibodies are found.
Collapse
Affiliation(s)
- C Seinturier
- Unité de médecine vasculaire 10 C, Département pluridisciplinaire de médecine, CHU de Grenoble, BP 217, 38043 La Tronche Cedex.
| | | | | | | | | |
Collapse
|